The relation between C reactive protein and age related macular degeneration in the Cardiovascular Health Study

G McGwin, T A Hall, A Xie, C Owsley

Aim: To test the hypothesis that individuals with age related macular degeneration (AMD) have increased C reactive protein (CRP) levels.

Methods: A cross sectional study design using data from the Cardiovascular Health Study (CHS), a longitudinal study that enrolled older adults from four communities in the United States from 1989 to 1990, was employed to investigate the existence of an association between AMD and CRP levels in this population. Fundus photographs from 1997 and 1998 were used to identify individuals with (n = 390) and without AMD (n = 2365). The association between AMD and CRP levels (measured at baseline) was compared, adjusting for the potentially confounding effect of demographic, lifestyle, and health related characteristics.

Results: Among the 2755 CHS participants with gradable fundus photographs, 390 were identified as having AMD. Overall, median CRP levels among those with AMD (1.76 mg/l) were similar to those without AMD (1.77 mg/l). CRP levels were categorised into quartiles and compared between those with and without AMD. Relative to those in the lowest quartile (0.07–0.93 mg/l), the odds ratios (OR) in the higher quartiles, adjusted for demographic, lifestyle, and health related characteristics were increased but not statistically significant (0.94–1.77 mg/l: OR = 1.14, 95% CI 0.82 to 1.60; 1.78–3.04 mg/l: OR = 1.24, 95% CI 0.88 to 1.75; >3.04 mg/l: OR = 1.24, 95% CI 0.87 to 1.78).

Conclusions: In the CHS, there is no evidence that CRP levels are associated with AMD. These data do not support the theory alleging non-specific systemic inflammation in the aetiology and natural history of this disease.

Abbreviations: AMD, age related macular degeneration; BMI, body mass index; CRP, C reactive protein; HDL, high density lipoprotein; LDL, low density lipoprotein; RPE, retinal pigmented epithelium.
1989 and 1990 and an additional 687 black subjects from Forsyth, Sacramento, and Allegheny Counties in 1992 and 1993). Differences between those who did and did not participate in the study have been reported elsewhere. At baseline and annually thereafter, physical and laboratory evaluations were performed.

Subject selection
One of the primary variables of interest for this study is AMD status. To ascertain the presence of AMD and other retinal diseases, retinal photography was added to the study protocol for the 1997–98 examination. Retinal photographs were taken of one randomly selected eye. Participants spent 5 minutes in a dark room before photographs were taken. The retinal photography protocol was similar to those reported for the Atherosclerosis Risk in Communities study that has been previously described. Of the 4447 surviving participants, 4249 participated in the 1997–98 examination; however, only 3074 of these participants were examined at a study clinic wherein fundus photography was performed. Of these participants, retinal photographs were available on 2755; this is the segment of the cohort used in this study. A comparison between those surviving cohort members with and without fundus photographs has been previously published.

Variable selection and definition
The presence of AMD was defined based upon information obtained from the retinal photographs. Photographs were graded in a masked fashion using a modified Wisconsin ARM classification scheme as previously described. Early AMD was defined as the presence of soft drusen alone, RPE depigmentation alone, or a combination of soft drusen with increased retinal pigment and/or depigmentation in the absence of late AMD. Late AMD was defined as the presence of exudative macular degeneration or pure geographic atrophy. Of the 2755 study subjects, 390 were identified as having AMD (360 early; 30 late). For the purpose of this study, cases of early and late AMD were combined into a single group, as there were too few subjects with late AMD for meaningful analysis. When the analyses were conducted including and excluding the subjects with late AMD, the study results were similar.

C reactive protein was measured at baseline by use of an enzyme linked immunosorbent assay developed at the CHS central blood laboratory. It is a colorimetric competitive immunoassay that uses purified protein and polyclonal anti-CRP antibodies. The interassay coefficient of variation is 5.3.

In addition to demographic characteristics (age, sex, race), information pertaining to specific behavioural and medical characteristics was also extracted from the CHS data files. With respect to behavioural characteristics, information regarding smoking (never, former, and current) and alcohol consumption (ever, never) was obtained. Variables for body mass index (BMI), the presence of selected medical conditions (diabetes, hypertension, stroke, cardiovascular disease), cholesterol levels (HDL, LDL, total), and blood pressure (systolic, diastolic) were also extracted from the CHS data files. These variables were selected as they were considered potential confounders for the association between AMD and CRP as previously described though not all variables previously described were available in the CHS data files. Details regarding the collection and definition of these variables are available elsewhere.

Statistical analysis
Demographic and medical characteristics were compared between those with and without AMD using \( t \) and \( \chi^2 \) tests for continuous and categorical variables, respectively. CRP was categorised into quartiles based upon the entire distribution of CRP values for the study population. With AMD status and CRP quartiles as the dependent and independent variables, respectively, logistic regression was used to calculate odds ratios for the study population.

Table 1

<table>
<thead>
<tr>
<th>Variable</th>
<th>Any AMD (n = 390)</th>
<th>No AMD (n = 2365)</th>
<th>p Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Demographic</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Age (years), % (n)</td>
<td>16.4 (64)</td>
<td>28.3 (668)</td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td>&lt;=76</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>76-77</td>
<td>19.0 (74)</td>
<td>22.2 (526)</td>
<td></td>
</tr>
<tr>
<td>78-81</td>
<td>28.7 (112)</td>
<td>27.2 (643)</td>
<td></td>
</tr>
<tr>
<td>&gt;81</td>
<td>35.9 (140)</td>
<td>22.3 (528)</td>
<td></td>
</tr>
<tr>
<td>Sex, % male (n)</td>
<td>41.0 (160)</td>
<td>40.0 (946)</td>
<td>0.7019</td>
</tr>
<tr>
<td>Race, % white (n)</td>
<td>91.8 (358)</td>
<td>82.6 (1953)</td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td>Behavioural</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Smoking status, % (n)</td>
<td></td>
<td></td>
<td>0.8387</td>
</tr>
<tr>
<td>Never</td>
<td>50.0 (194)</td>
<td>48.4 (1133)</td>
<td></td>
</tr>
<tr>
<td>Former</td>
<td>43.3 (168)</td>
<td>44.8 (1048)</td>
<td></td>
</tr>
<tr>
<td>Current</td>
<td>6.7 (26)</td>
<td>6.9 (161)</td>
<td></td>
</tr>
<tr>
<td>Alcohol consumption, % (n)</td>
<td></td>
<td></td>
<td>0.3866</td>
</tr>
<tr>
<td>Never</td>
<td>45.1 (176)</td>
<td>42.8 (1011)</td>
<td></td>
</tr>
<tr>
<td>Ever</td>
<td>54.9 (214)</td>
<td>57.2 (1352)</td>
<td></td>
</tr>
<tr>
<td>Medical</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>BMI (kg/m²), mean (SD)</td>
<td>26.3 (3.9)</td>
<td>26.8 (4.0)</td>
<td>0.0215</td>
</tr>
<tr>
<td>Selected medical conditions, % (n)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Diabetes</td>
<td>9.9 (38)</td>
<td>13.2 (309)</td>
<td>0.0776</td>
</tr>
<tr>
<td>Hypertension</td>
<td>48.5 (189)</td>
<td>49.5 (1170)</td>
<td>0.7117</td>
</tr>
<tr>
<td>Stroke</td>
<td>3.9 (15)</td>
<td>5.4 (127)</td>
<td>0.2073</td>
</tr>
<tr>
<td>Cardiovascular disease</td>
<td>25.9 (101)</td>
<td>26.4 (624)</td>
<td>0.8955</td>
</tr>
<tr>
<td>HDL cholesterol (mg/dl), mean (SD)</td>
<td>55.0 (14.6)</td>
<td>54.3 (14.5)</td>
<td>0.3945</td>
</tr>
<tr>
<td>LDL cholesterol (mg/dl), mean (SD)</td>
<td>123.4 (30.8)</td>
<td>126.6 (31.7)</td>
<td>0.0679</td>
</tr>
<tr>
<td>Total serum cholesterol (mg/dl), mean (SD)</td>
<td>200.8 (31.2)</td>
<td>204.8 (33.2)</td>
<td>0.0366</td>
</tr>
<tr>
<td>Blood pressure, mean (SD)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Systolic</td>
<td>131.4 (18.6)</td>
<td>132.3 (20.3)</td>
<td>0.3645</td>
</tr>
<tr>
<td>Diastolic</td>
<td>66.2 (10.4)</td>
<td>66.9 (11.0)</td>
<td>0.2311</td>
</tr>
</tbody>
</table>

AMD, age related macular degeneration; BMI, body mass index; HDL, high density lipoprotein; LDL, low density lipoprotein; SD, standard deviation.
RESULTS

Study participants with AMD tended to be older and were more likely to be White compared to those without AMD; there was no difference with respect to sex (table 1). Smoking and alcohol consumption was also similar between the groups. Those with AMD had a significantly lower BMI though the absolute difference was very small. Hypertension and cardiovascular disease were common in both groups; diabetes and stroke less so. None of these differences was statistically significant. HDL cholesterol levels were similar among those with and without AMD. LDL and total serum cholesterol values were, on average, lower among those with AMD; however, the p value for LDL cholesterol was of borderline statistical significance (p = 0.0679). Blood pressure, both systolic and diastolic, did not differ between the groups.

Table 2 presents odds ratios (OR) and 95% confidence intervals (CI) for the association between AMD and CRP. The unadjusted and age, sex, and race adjusted associations provide no evidence of an association between AMD and CRP. When additional adjustment for medical characteristics described above, to evaluate the potential modifying effect of smoking as described by Seddon et al, these associations were also calculated stratified by smoking status (ever vs never). p Values of ≤0.05 were considered statistically significant.

Table 3 presents odds ratios (OR) and 95% confidence intervals (CI) for the association between AMD and CRP. The unadjusted ORs suggest no significant relation between AMD and CRP for either never or ever smokers (table 4). Following adjustment for demographic and medical characteristics, for never smokers all of the ORs are increased yet the only significant association is observed for the 3rd quartile (OR 1.65; 95% CI 1.01 to 2.69). Among ever smokers, adjustment had little impact on the magnitude of the associations.

DISCUSSION

There have been several epidemiological investigations of the relation between inflammation and AMD. Klein et al sought to examine the relation between diseases (that is, emphysema, gout) and markers (that is, white blood cell count, serum albumin, platelet count) associated with systemic inflammation and AMD. They reported modest associations between these diseases and markers, except platelet count, with AMD. Other similar studies have not reported consistent findings. For example, white blood cell count was found to be associated with AMD in one study but three others reported no such association.

Our results are contrary to the only other study on this topic by Seddon et al, which reported that increased CRP levels were associated with an increased risk of AMD. Moreover, this study reported that advanced cases of AMD were associated with higher levels of CRP than were cases with essentially no drusen. In the Seddon et al study and the present study there was a difference in the distribution of CRP values that produced different quartiles; however, when the quartiles used by Seddon et al were applied to the CHS data, we still observed no association. Regarding cigarette smoking, Seddon et al reported that the risk of AMD was

### Table 2

<table>
<thead>
<tr>
<th>C reactive protein groups</th>
<th>AMD (n)</th>
<th>Without AMD (n)</th>
<th>OR (95% CI)*</th>
<th>OR (95% CI)†</th>
<th>OR (95% CI)‡</th>
</tr>
</thead>
<tbody>
<tr>
<td>&lt;0.93 mg/l</td>
<td>97</td>
<td>593</td>
<td>1.0</td>
<td>1.00 (0.73–1.35)</td>
<td>1.00 (0.73–1.35)</td>
</tr>
<tr>
<td>0.93–1.77 mg/l</td>
<td>98</td>
<td>573</td>
<td>1.05 (0.77–1.42)</td>
<td>1.04 (0.77–1.41)</td>
<td>1.00 (0.73–1.35)</td>
</tr>
<tr>
<td>1.78–3.04 mg/l</td>
<td>99</td>
<td>580</td>
<td>1.06 (0.78–1.44)</td>
<td>1.05 (0.77–1.42)</td>
<td>1.09 (0.80–1.49)</td>
</tr>
<tr>
<td>3.05–107.97 mg/l</td>
<td>95</td>
<td>583</td>
<td>1.14 (0.82–1.60)</td>
<td>1.24 (0.88–1.75)</td>
<td>1.24 (0.87–1.78)</td>
</tr>
</tbody>
</table>

**AMD**, age related macular degeneration; n, number; OR, odds ratio; CI, confidence intervals.

*Unadjusted.
†Adjusted for age, sex, and race.
‡Adjusted for all variables appearing in table 1.

### Table 3

<table>
<thead>
<tr>
<th>C reactive protein groups</th>
<th>AMD (n)</th>
<th>Without AMD (n)</th>
<th>OR (95% CI)*</th>
<th>OR (95% CI)†</th>
<th>OR (95% CI)‡</th>
</tr>
</thead>
<tbody>
<tr>
<td>0.2–1.2 mg/l</td>
<td>133</td>
<td>783</td>
<td>1.0</td>
<td>1.09 (0.81–1.47)</td>
<td>0.99 (0.68–1.44)</td>
</tr>
<tr>
<td>1.2–2.7 mg/l</td>
<td>130</td>
<td>844</td>
<td>0.91 (0.70–1.18)</td>
<td>1.09 (0.81–1.47)</td>
<td>0.99 (0.68–1.44)</td>
</tr>
<tr>
<td>2.7–6.5 mg/l</td>
<td>84</td>
<td>452</td>
<td>1.18 (0.87–1.60)</td>
<td>1.10 (0.75–1.61)</td>
<td>1.10 (0.75–1.61)</td>
</tr>
<tr>
<td>6.5–117.0 mg/l</td>
<td>42</td>
<td>250</td>
<td>1.39 (0.99–1.96)</td>
<td>1.09 (0.70–1.70)</td>
<td>1.09 (0.70–1.70)</td>
</tr>
</tbody>
</table>

**AMD**, age related macular degeneration; n, number; OR, odds ratio; CI, confidence intervals.

*Unadjusted.
†Adjusted for age, sex, and race.
‡Adjusted for all variables appearing in table 1.
highest among those with high CRP values who were also smokers. The prior analysis of the CHS data did not evaluate the effect of smoking on the association between CRP and AMD.\(^1\) We have redressed this issue in the current study and found, in general, that smoking had no effect on the association between CRP and AMD. It should be noted that the study by Seddon et al contained more patients with advanced AMD than in the current study and in that study CRP values were significantly increased only in this group. If CRP is only associated with advanced disease then the current study may not have had a sufficient number of subjects to detect an association.

If an association between AMD and CRP truly exists, limitations of the current study may explain why such an association was not observed. The CHS participants included in the present study represent only a subset of the entire CHS cohort. Of those alive at the 1997–98 examination, roughly 62% had a retinal photograph available and were therefore able to participate in the current study. CRP levels were higher among those who did not have a retinal photograph;\(^2\) if these individuals were also more likely to have AMD then the results of the current study may be biased towards the null. Additionally, as increased mortality has recently been reported in patients with AMD,\(^3\) the high mortality rate in the current study (25%) may have reduced the number of patients with AMD and also predisposed toward a null result. It is also important to note that whereas CRP measurements were based on blood samples taken at the time of the baseline examination, retinal photographs were taken approximately 10 years later. It would have been optimal if disease status was known at the baseline examination thereby allowing for the exclusion of prevalent cases. By starting with a cohort of subjects free of AMD, the temporal relation between CRP and the incidence of AMD would have been easier to establish. On the other hand, individuals do have stable CRP concentrations over time;\(^4\) thus, although a temporal relation could not be established, the CRP levels taken during the study should represent levels before and after the retinal photographs were taken.

There is mounting evidence from laboratory based studies that inflammation plays a key role in the pathogenesis of AMD.\(^5\) In contrast, epidemiological investigations have produced equivocal results. There are several possible reasons to explain this lack of agreement between the laboratory and clinical literature, the most obvious of which is the different capabilities of laboratory and clinical settings to detect the same physiological events. The design of laboratory based studies using human donor eyes allows for markers of inflammation to be measured directly in the structures of the eye whereas clinical studies must rely on systemic measurements such as CRP and plasma fibrinogen. Moreover, given the fact that the retina makes up an extremely small part of the body and that the portion involved in AMD is even smaller, the local inflammatory reaction reported to exist therein by laboratory studies would not be expected to create detectable levels of acute phase reactants in the bloodstream anymore than a small laceration would. Therefore, if CRP or other acute phase reactants were found to be associated with AMD, the relation would more likely be aetiological than consequential. However, the flaw in this line of reasoning is the lack of overwhelming evidence for a relation between AMD and conditions associated with an increased CRP (for example, obesity,\(^6\) hypertension,\(^7\) diabetes,\(^8\) coronary artery disease,\(^9\) and osteoarthritis\(^10\)). Although the Age-Related Eye Disease Study (AREDS) found some of these conditions (obesity, hypertension, and arthritis) to be associated with AMD, the results were modest.\(^11\) A recent study by Tomany et al pooled data from the Beaver Dam, Blue Mountains, and Rotterdam Eye studies and found that only smoking increased the risk of AMD.\(^12\) No association was found for diabetes, hypertension, obesity, or history of myocardial infarction.\(^13\) Furthermore, a recent comprehensive examination of the existing literature concerning risk factors for AMD, Klein et al concluded that only smoking, hypertension, and cataract surgery have consistently been related to AMD.\(^14\) With respect to smoking, we did not observe an association between AMD and smoking status. However, despite the seemingly well accepted association between smoking and AMD, in reality the literature provides less consistent evidence for such an association. Although the literature provides consistent support for an association between smoking and advanced AMD and its associated lesions, there is far less support for a relation with early AMD, which were the majority of cases in the current study.

It is also important to consider the physiology of the blood retinal barrier (BRB). The BRB maintains the microenvironment of the retina through selective transport and the tight junctions of the retinal vascular endothelium and the retinal pigmented epithelium.\(^1\) This creates an immune privileged site that aggressively prevents inflammation so that the exact microanatomy required for vision can be maintained.\(^16\) Thus, the extent to which systemic markers of inflammation could impact the localised processes in the eye, at most, would be minimal. Another significant limitation of most laboratory based research is that the observed associations are cross sectional in nature. These studies measure inflammatory markers coincident with the presence of disease. This precludes the determination of inflammation as a precursor or consequence of the disease. Of note, several observational studies also suffer from this same limitation.

In summary, the results of this study do not support an association between a systemic marker of inflammation, specifically CRP, and AMD. The inability to measure localised inflammatory changes in an intact human eye represents one of the largest obstacles to effectively investigate the mounting laboratory research suggesting a pathological role for

| Table 4: Odds ratios and 95% confidence intervals for association between AMD and C-reactive protein according to smoking status |
|---------------------------------|-----------------|-----------------|-----------------|-----------------|
| C reactive protein groups | Never smokers | Ever smokers | |
| CRP group | OR (95% CI) | OR (95% CI) | OR (95% CI) | |
| <0.93 mg/l | 1.00 (0.79–1.26) | 1.00 (0.75–1.33) | 1.00 (0.76–1.39) |
| 0.93–1.77 mg/l | 1.09 (0.90–1.31) | 1.07 (0.89–1.29) | 1.07 (0.89–1.29) |
| 1.78–3.04 mg/l | 1.32 (1.06–1.64) | 1.29 (1.04–1.60) | 1.29 (1.04–1.60) |
| 3.05–107.97 mg/l | 1.17 (0.75–1.80) | 1.16 (0.78–1.74) | 1.16 (0.78–1.74) |

AMD, age related macular degeneration; CRP, C reactive protein; OR, odds ratio; CI, confidence intervals.

*Unadjusted.
†Adjusted for all variables appearing in table 1.
inflammation in AMD. Moreover, the cross sectional nature of most research to date, both laboratory and clinical, also hampers firm conclusions from being drawn. Future observational studies should attempt to resolve this issue and evaluate the association between CRP and other markers of inflammation in a prospective manner.

ACKNOWLEDGEMENTS
This research was supported by NIH grant R21 EY14071. Research to Prevent Blindness Inc, New York, NY, USA and the EyeSight Foundation of Alabama, Birmingham, AL, USA. Cynthia Owsley is a Research to Prevent Blindness Senior Scientific Investigator.

Authors’ affiliations
G McGwin, TA Hall, A Xie, C Owsley, Department of Ophthalmology, School of Medicine, University of Alabama at Birmingham, Birmingham, AL, USA
G McGwin, Department of Epidemiology and International Health, School of Public Health, University of Alabama at Birmingham, Birmingham, AL, USA
G McGwin, Section of Trauma, Burns, and Surgical Critical Care, Division of General Surgery, Department of Surgery, School of Medicine, University of Alabama at Birmingham, Birmingham, AL, USA

Competing interests: none declared

REFERENCES

www.bjophthal.com
The relation between C reactive protein and age related macular degeneration in the Cardiovascular Health Study
G McGwin, T A Hall, A Xie and C Owsley

Br J Ophthalmol 2005 89: 1166-1170
doi: 10.1136/bjo.2005.067397

Updated information and services can be found at:
http://bjo.bmj.com/content/89/9/1166

These include:

References
This article cites 44 articles, 9 of which you can access for free at:
http://bjo.bmj.com/content/89/9/1166#BIBL

Email alerting service
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Topic Collections
Articles on similar topics can be found in the following collections

Retina (1608)
Epidemiology (1068)

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/